BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%
Market cap
$10.9B
P/E
144×
Fwd P/E
16.1×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
150.58 40.35 32.65 19.91

+8 more quarters

P/S ratio
3.25 3.35 3.54 3.36
P/FCF ratio
15.27 14.32 15.90 12.59
P/Operating CF
65.84 49.28 114.39 28.21
P/B ratio
1.75 1.75 1.87 1.72
EV/Sales
4.22 3.26 3.39 3.24
EV/EBITDA
48.35 27.46 22.57 14.45
EV/FCF
19.84 13.93 15.24 12.13
Current Ratio
2.39 5.81 5.21 4.83
Net Debt/EBITDA
15.85 (5.44) 38.11 27.62
Debt/Equity
0.66 0.23 0.10 0.10
Earnings Yield
0.66% 2.48% 3.06% 5.02%
Free Cash Flow Yield
6.55% 6.98% 6.29% 7.94%
Free Cash Flow per Share
0.69 1.04 0.29 1.74
Book value per Share
32.68 32.27 31.74 31.54
Free Cash Flow
133.86 199.73 56.55 334.94
EV/EBIT
96.34 33.55 26.69 16.27
Other line items

Show all line items

Columns are period end dates